PRMT7 restricts CD8+ T cells expansion via the NF-κB pathway.
Nivine Srour, Kaixiu Luo, David Allard, Yan Xiong, Zhenbao Yu, Theodore Papadopoulos, François Santinon, Cheng-Hsun Hsieh, Anthony Parent, John Stagg, Simon Turcotte, Dalia Baršytė-Lovejoy, Stéphanie Lehoux, Sonia V. del Rincon, Jian Jun Jin, Stéphane Richard
This study identifies PRMT7 as a negative regulator of CD8+ T cell immunity and demonstrates a PROTAC degrader (MS54) that enhances anti-tumor responses by activating the NF-κB pathway.
Nature Communications · Sep 5, 2026Peer-reviewedMolecular Biology